Integra LifeSciences to buy Acclarent from Johnson & Johnson for $275M

Princeton-based Integra LifeSciences Holdings Corp. on Wednesday announced it agreed to buy ear, nose and throat procedures firm Acclarent from Ethicon, a unit of Johnson & Johnson, for $275 million in cash.

Integra said the deal, which expands its portfolio of ear, nose and throat products and technologies, also includes an additional $5 million based on the achievement of certain regulatory milestones.

“This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment. Acclarent’s culture of pioneering technologies aligns with Integra’s legacy of innovation to transform care and restore patients’ lives,” Jan De Witte, CEO and president of Integra LifeSciences, said. “We are looking forward to welcoming the Acclarent employees to the Integra team. Together, we can make a profound impact on the future of ENT and neurosurgery.”

Acclarent is headquartered in Irvine, California, and derives its revenues from U.S. product sales, which generated about $110 million in 2022 and gross margins in line with Integra’s company average. The company maintains research & development facilities in Irvine and Haifa, Israel, and uses third-party manufacturers.

“The ENT segment is an anatomical adjacency to neurosurgery. For example, this acquisition will provide opportunities for ENT and neurosurgeons to closely collaborate on tumor care using skull base approaches,” Mike McBreen, president of the Codman Specialty Surgical division, said. “Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, allowing us to deliver future innovation not only within ENT, but also across our other CSS technology platforms.”